title: Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid.
abstract: OBJECTIVE
  Idiopathic pulmonary fibrosis (IPF) is a slowly progressive disease with a poor prognosis. Acute exacerbation is the worst stage in the clinical course of IPF, as the condition is unresponsive to most conventional therapies. Corticosteroids and other immunosuppressive drugs have been attempted for the treatment of acute exacerbation, but only with very limited effectiveness. This study was performed to examine the effect of cyclosporin A (CsA) on acute exacerbation of IPF.
  
  
  METHODS
  Thirteen patients with acute exacerbation of IPF were retrospectively studied. All 13 patients received pulse-therapy with methylprednisolone (1,000 mg per day for 3 days), followed by oral prednisolone (40-60 mg per day). Seven patients were received CsA (1.0-2.0 mg/kg per day) after the treatment with corticosteroids. We attempted to keep the blood trough level of CsA between 100 and 150 ng/ml.
  
  
  RESULTS
  Among the 7 patients treated with CsA, 4 patients have survived for 60, 120, 276 and 208 weeks, respectively; 2 did not respond to pulse-therapy with methylprednisolone and died within 8 weeks after the start of CsA treatment. The other patient experienced re-exacerbation and died 87 weeks after the discontinuation of CsA due to the development of viral encephalitis. In contrast, all 6 patients treated without CsA died within 66 weeks after the onset of acute exacerbation. Four of these patients responded to pulse-therapy with methylprednisolone, but their condition deteriorated again while the subsequent prednisolone was being tapered.
  
  
  CONCLUSIONS
  CsA seems to prevent re-exacerbation of IPF and improve the patients' chances for long-term survival.
authors.affiliation: Pulmonary Medicine, Tokyo Medical and Dental University, Tokyo.
authors.forename: Naohiko
authors.initials: N
authors.lastname: Inase
authors.forename: Megumi
authors.initials: M
authors.lastname: Sawada
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Ohtani
authors.forename: Shuji
authors.initials: S
authors.lastname: Miyake
authors.forename: Susumu
authors.initials: S
authors.lastname: Isogai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sakashita
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Yoshizawa
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage*; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D008775:Methylprednisolone